NCT04901299撤回2 期
An Open-Label Phase II Trial of Fulvestrant And Neratinib in Previously Treated HRPositive, HER2-Negative Metastatic Breast Cancer Subjects Assessed With a Test Measuring Live Cell HER2 Signaling Function
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Objective response rates (ORR)
研究概览
简要总结
This is a Phase 2 open label, multi-center non-randomized interventional study designed to evaluate the safety and efficacy of combining Neratinib plus Fulvestrant in previously treated metastatic HR-positive, HER2-negative breast cancer.
- This research study involves the study drug Neratinib
- The standard of care drug Fulvestrant
详细描述
-
The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
-
This research study involves the study drug Neratinib
-
The standard of care drug Fulvestrant
-
It is expected that about 25 people will take part in this research study.
-
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
-
The U.S. Food and Drug Administration (FDA) has not approved Neratinib for this specific disease but it has been approved for other uses.
-
The FDA has approved Fulvestrant as a treatment option for this disease. Fulvestrant is a standard of care drug that will be administered.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult (≥ 18 years of age).
- •Histologically or cytologically confirmed stage IV (metastatic) breast cancer. PI approval is needed for patients who do not have source documentation of histologically confirmed stage IV (metastatic) breast cancer, but otherwise have known metastatic breast cancer.
- •Participants must have biopsy proven HR+, i.e ER positive (ER+) and/or PR positive (PR+), HER2 non-amplified (negative), invasive breast cancer. ER, PR, and HER2 positivity would be determined per institutional (local) testing, with HR+/HER2 nonamplified (negative) status for this trial determined as per 2020 ASCO/CAP guidelines, in a biopsy/surgical specimen analyzed for ER/PR/HER
- •Patients with "ER or PR low positive" (<10%) as per updated ASCO/CAP 2020 guidelines can be considered.Confirmation of adequate (15-20 unstained slides cut at 5-10 μm or 1 block) archival tissue (primary or metastatic) required before study entry. If adequate tissue not available, PI approval is required prior to study entry.
- •Previously treated with no more than three prior chemotherapy regimens (no limit on prior endocrine-based regimens (including CDK4/6i and PI3K pathway inhibitors) or immunotherapy). In patients with disease recurrence during/within 12 months of (neo)adjuvant therapy, the (neo)adjuvant therapy would count as one prior regimen for this criterion. Radiation therapy or local therapy/surgery would not count as prior regimen for this criterion. Patient who discontinued chemotherapy during/after only one cycle and/or due to adverse effects without disease progression would not count the treatment/regimen as prior regimen for this criterion. Antibody drug conjugate and PARP inhibitor treatment would count as chemotherapy regimen for this criterion.
- •Hyperactive HER2 signaling activity based on results from the CELsignia test (separate pre-screening test).
- •Postmenopausal women with locally advanced or metastatic BC. Patients must be postmenopausal women as defined by one of the following:
- •Women > 60 years OR
- •Women ≤ 60 years, and any one of the following:
- •LH and FSH level in the postmenopausal range according to institutional standards
- •s/p post bilateral surgical oophorectomy
- •Premenopausal/perimenopausal women on gonadotropin-releasing hormone agonist (to be continued during study) and estradiol level in the postmenopausal range according to institutional standards.
- •ECOG performance status = 0-2
- •Measurable disease as per RECIST Version 1.
- •Ability to understand and the willingness to undergo tissue biopsy for HER2 testing (CELsignia test). Patient has signed the Informed Consent (ICF) prior to any screening procedures being performed and is able to comply with protocol requirements.
- •At least 2 weeks beyond treatment (chemotherapy, targeted therapy, immunotherapy, and/or radiation therapy) or major surgery and recovered from all acute toxicities prior to randomization. (adverse events from prior anti-cancer agents need to be grade 1 or lower; grade 2 alopecia or peripheral neuropathy is permitted).
- •Patient has adequate bone marrow and organ function as defined by the following laboratory values at screening:
- •Absolute neutrophil count ≥ 1.5 × 109/L
- •Platelets ≥ 75 × 109/L
- •Hemoglobin ≥ 9.0 g/dL (transfusion permitted)
- •GFR or creatinine clearance ≥50 mL/min (either permitted)
- •In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 x ULN. If the patient has liver metastases, ALT and AST <5 x ULN.
- •Total bilirubin ≤1.5.0 x ULN, or direct bilirubin ≤3 x ULN in patients with well documented Gilbert's Syndrome.
排除标准
- •Participants who have received prior neratinib or any anti-HER2 therapy for metastatic disease will not be eligible. Participants who have received prior fulvestrant (or any other endocrine therapy) will be eligible. Patients with known HER2 activating mutations (either plasma and/or tissue-based genotyping) will not be eligible.
- •Participants with increasing/progressive CNS metastatic disease. Patients with asymptomatic or stable CNS metastasis are eligible, provided metastasis radiologically non-progressing for at least two weeks, and patient is not actively taking steroids (more than 20 mg of prednisone or equivalent dose).
- •Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
- •Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality including any of the following:
- •History of angina pectoris, symptomatic pericarditis, coronary artery bypass graft (CABG) or myocardial infarction within 6 months prior to study entry.
- •Known LVEF <50% (by ECHO or MUGA) and/or known documented cardiomyopathy.
- •History of cardiac failure, significant/symptomatic bradycardia, Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome or any of the following:
- •Known risk to prolong the QT interval or induce Torsade's de Pointes.
- •On screening, QTcF >470 screening ECG.
- •HIV-positive participants on combination antiretroviral therapy are ineligible. These participants are at increased risk of lethal infections when treated with marrow suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
- •Pregnant women are excluded from this study because the safety of study medications is not established in pregnant women.
- •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, or fertile men, unless they are using highly effective methods of contraception throughout the study and after study drug discontinuation (till seven months in women and four months in males, post-study). Male patient should not donate sperm while on treatment and up to 6 months after last dose. Women are considered postmenopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential. Highly effective contraception methods include:
- •Total abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
- •Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
- •Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
- •In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Note: While oral contraceptives are allowed, they should be used in conjunction with a barrier method of contraception due to unknown effect of drug-drug interaction.
研究组 & 干预措施
NERATINIB + FULVESTRANT
Experimental
After the screening procedures confirm participation in the research study.
- Each Cycle = 28 days
- Neratinib (oral, once daily)
- Fulvestrant, injection, on 2 days for cycle 1, then one time per cycle thereafter
干预措施: NERATINIB (Drug)
NERATINIB + FULVESTRANT
Experimental
After the screening procedures confirm participation in the research study.
- Each Cycle = 28 days
- Neratinib (oral, once daily)
- Fulvestrant, injection, on 2 days for cycle 1, then one time per cycle thereafter
干预措施: FULVESTRANT (Drug)
结局指标
主要结局
Objective response rates (ORR)
时间窗: Up to 33 Months
ORR is defined as the proportion of patients with a confirmed CR or PR per Investigator's assessment per RECIST v1.1
次要结局
- Overall survival (OS)(Up to 33 Months)
- CELsignia score and Progression Free Survival(up to 33 months)
- Progression-Free Survival (PFS)(Up to 33 Months)
- Number of Participants with Treatment Related Adverse Events as Assessed NCI CTCAE (version 5.0)(first treatment day to death up to 33 Months)
- CELsignia score and CB(Up to 33 Months)
- CELsignia score and molecular alterations in plasma(Up to 33 Months)
- Time-to-Tumor Response (TTR)(Up to 33 Months)
- Cumulative Objective Response Incidence(Up to 33 Months)
- Duration of response (DOR)(Up to 33 Months)
- CELsignia score and Objective Response(Up to 33 Months)
研究者
Aditya Bardia
Principal Investigator
Massachusetts General Hospital
研究点 (2)
Loading locations...
相似试验
终止
2 期
To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).Warm Autoimmune Hemolytic AnemiaNCT04253236Immunovant Sciences GmbH5
已完成
2 期
Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast CancerNeoplasm MetastasisBreast CancerNCT00377559Catharina Ziekenhuis Eindhoven70
撤回
2 期
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaPrimary Central Nervous System LymphomaNCT03120000PIQUR Therapeutics AG
已完成
2 期
PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaPrimary Central Nervous System LymphomaNCT02669511PIQUR Therapeutics AG21
已完成
2 期
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor TherapyChronic Lymphocytic LeukemiaNCT02141282AbbVie127